Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, ...

Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder cancers will ...

How much a stock's price changes over time is important for most investors, since price performance can both impact your ...

Transaction value based on SEC Form 4 weighted average purchase price ($52.89); post-transaction value based on June 18, 2026 market close. Veracyte is a healthcare diagnostics company specializing in ...

Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain. With a ...

Veracyte, Inc. VCYT delivered fourth-quarter 2025 adjusted earnings of 53 cents per share, up 47.2% from the year-ago period. The bottom line beat the Zacks Consensus Estimate by 30.06%. The company’s ...

Veracyte’s latest analyst update comes with no change in the price target, which can be just as informative as a revision.